Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer
Cancer, 04/23/2012Epstein AS et al.
Thromboembolic events (TEs) are common in exocrine pancreatic cancer, with coagulopathy, erythropoietin–stimulating agent use, and underweight body mass index (BMI) influencing thrombosis timing. TEs, particularly early ones, confer a significantly worse prognosis, suggesting a biological significance, underscoring the relevance of ongoing prophylaxis trials, and raising the question of whether early TEs should be considered a stratification factor for clinical trials.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.